SRDX (Surmodics) Total Debt per Share: $2.28 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
View Full Analysis

What is Surmodics Total Debt per Share?

Surmodics SRDX -0.01% 51 Total Debt per Share is $2.28 as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100.

$2.28 (As of Jun. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Surmodics's Total Debt Per Share for the quarter that ended in Jun. 2025 was $2.28.

Surmodics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Surmodics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Total Debt per Share Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.99 1.06 2.35 2.32

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.35 2.32 2.31 2.29 2.28
SRDX
51GF Score
Surmodics Inc SRDX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Total Debt per Share Calculation

Surmodics's Total Debt Per Share for the fiscal year that ended in Sep. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(32.2+1.0)/14.3
=2.32

Surmodics's Total Debt Per Share for the quarter that ended in Jun. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(31.6+1.0)/14.3
=2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $2.28 mean?
Surmodics (SRDX) has a Total Debt per Share of $2.28 as of Jun. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Surmodics and its competitors.
Is Surmodics' Total Debt per Share too high?
Surmodics' current Total Debt per Share is $2.28. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Total Debt per Share compare to CBLL and OFIX?
Surmodics' Total Debt per Share of $2.28 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Surmodics and its competitors. Surmodics's current Total Debt per Share is $2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Total Debt per Share of $2.28. The current Total Debt per Share is $2.28. Surmodics' overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Surmodics (SRDX), the current Total Debt per Share is $2.28 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price